Access to the tracheal pulmonary pathway in small rodents

Ribeiro, Renato Niemeyer de Freitas; Ferreira, Isabeliza M. E. S. R.; Figueiredo, Israel; Vericimo, Mauricio Afonso

doi:10.5935/1676-2444.20150032

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We implemented a novel method that employed in situ infusion of the RNA preserving reagent RNAlater (Thermo Fisher Scientific, Waltham, MA, USA) into the lungs of the animals through the trachea under deep anesthesia. A puncture tracheotomy technique [ 13 , 14 ] enabled infusion of 1 mL of RNAlater into the lungs through the trachea using a syringe attached to an IV catheter ( Figure 1 , top panel). After infusion of RNAlater, the thoracic cavity was dissected, the lungs were removed and immediately washed in PBS by immersion and subsequently placed in a 50 mL test tube containing 25 mL RNAlater.…”

Section: Methodsmentioning

confidence: 99%

Novel RNA Extraction Method for Dual RNA-seq Analysis of Pathogen and Host in the Early Stages of Yersinia pestis Pulmonary Infection

et al. 2021

View full text Add to dashboard Cite

Pneumonic plague, caused by Yersinia pestis, is a rapidly progressing lethal infection. The various phases of pneumonic plague are yet to be fully understood. A well-established way to address the pathology of infectious diseases in general, and pneumonic plague in particular, is to conduct concomitant transcriptomic analysis of the bacteria and the host. The analysis of dual RNA by RNA sequencing technology is challenging, due the difficulties of extracting bacterial RNA, which is overwhelmingly outnumbered by the host RNA, especially at the critical early time points post-infection (prior to 48 h). Here, we describe a novel technique that employed the infusion of an RNA preserving reagent (RNAlater) into the lungs of the animals, through the trachea, under deep anesthesia. This method enabled the isolation of stable dual mRNA from the lungs of mice infected with Y. pestis, as early as 24 h post-infection. The RNA was used for transcriptomic analysis, which provided a comprehensive gene expression profile of both the host and the pathogen.

show abstract

Section: Methodsmentioning

confidence: 99%

Novel RNA Extraction Method for Dual RNA-seq Analysis of Pathogen and Host in the Early Stages of Yersinia pestis Pulmonary Infection

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Particles applied by oropharyngeal aspiration or by intratracheal intubation can partly be cleared by mucociliary clearance because solutions are applied at the beginning of the trachea. Since the latter techniques are atraumatic, they are regarded as more physiologic than intratracheal instillation (Fröhlich & Salar-Behzadi, 2014 ; Ribero et al., 2015 ). The applied particle dose is influenced by variable loss in the application device.…”

Section: In Vitro Testingmentioning

confidence: 99%

Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening

Frőhlich

2017

Drug Delivery

View full text Add to dashboard Cite

To cite this article: Eleonore Fröhlich (2017) Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening, Drug Delivery Oral delivery is the most common mode of systemic drug application. Inhalation is mainly used for local therapy of lung diseases but may also be a promising route for systemic delivery of drugs that have poor oral bioavailability. The thin alveolar barrier enables fast and efficient uptake of many molecules and could deliver small molecules and proteins, which are susceptible to degradation and show poor absorption by oral application. The low rate of biotransformation and proteolytic degradation increases bioavailability of drugs but accumulation of not absorbed material may impair normal lung function. This limitation is more relevant for compounds that should be systematically active because higher doses have to be applied to the lung. The review describes processes that determine absorption of orally inhaled formulations, namely dissolution in the lung lining fluid and uptake and degradation by alveolar epithelial cells and macrophages. Dissolution testing in simulated lung fluid, screening for cytotoxicity and pro-inflammatory action in respiratory cells and study of macrophage morphology, and phagocytosis can help to identify adverse effects of pulmonary formulations. ARTICLE HISTORY

show abstract

Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment

Fayyaz,

EL-Massik,

Bahey-El-Din

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Access to the tracheal pulmonary pathway in small rodents

Cited by 4 publications

References 41 publications

Novel RNA Extraction Method for Dual RNA-seq Analysis of Pathogen and Host in the Early Stages of Yersinia pestis Pulmonary Infection

Novel RNA Extraction Method for Dual RNA-seq Analysis of Pathogen and Host in the Early Stages of Yersinia pestis Pulmonary Infection

Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening

Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment

Contact Info

Product

Resources

About